**Shares of drugmaker Arcutis Biotherapeutics ARQT.O rise 12.9% to $16.91
** Co says it has agreed to temporarily pause a patent lawsuit with Israel-based Padagis regarding the latter attempting to produce a generic version of ARQT's Zoryve
** Zoryve is used to treat skin disorders including plaque psoriasis, seborrheic dermatitis and atopic dermatitis
** As part of the agreement, Padagis will keep Arcutis updated on any communication with the FDA about their generic version of Zoryve
** The patent for Zoryve is protected until at least 2037
** Including session's moves, ARQT stock up 19.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。